<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23352749</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>381</Volume><Issue>9871</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.</ArticleTitle><Pagination><StartPage>1037</StartPage><EndPage>1045</EndPage><MedlinePgn>1037-45</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) outbreaks are a socioeconomic burden, especially in the western Pacific region. Results of phase 1 clinical trials suggest an EV71 vaccine has a clinically acceptable safety profile and immunogenicity. We aimed to assess the best possible dose and formulation, immunogenicity, and safety profile of this EV71 vaccine in healthy Chinese children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomised, double-blind, placebo-controlled, phase 2 trial was undertaken at one site in Donghai County, Jiangsu Province, China. Eligible participants were healthy boys or girls aged 6&#x2013;36 months. Participants were randomly assigned (1:1:1:1:1) to receive either 160 U, 320 U, or 640 U alum-adjuvant EV71 vaccine, 640 U adjuvant-free EV71 vaccine, or a placebo (containing alum adjuvant only), according to a blocked randomisation list generated by SAS 9.1. Participants and investigators were masked to the assignment. The primary endpoint was anti-EV71 neutralising antibody geometric mean titres (GMTs) at day 56, analysed according to protocol. The study is registered with ClinicalTrials.gov, number NCT01399853.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We randomly assigned 1200 participants, 240 (120 aged 6&#x2013;11 months [infants] and 120 aged 12&#x2013;36 months [children]) of whom were assigned to each dose. 1106 participants completed the study and were included in the according-to-protocol analysis. The main reasons for dropout were withdrawal of consent and refusal to donate a blood sample. Infants who received the 640 U adjuvant vaccine had the highest GMTs on day 56 (742&#xb7;2 [95% CI 577&#xb7;3&#x2013;954&#xb7;3]), followed by those who received the 320 U formulation (497&#xb7;9 [383&#xb7;1&#x2013;647&#xb7;0]). For children, those who received the 320 U formulation had the highest GMTs on day 56 (1383&#xb7;2 [1037&#xb7;3&#x2013;1844&#xb7;5]). Participants who received the vaccine had significantly higher GMTs than did who received placebo (p&lt;0&#xb7;0001). For the subgroup of participants who were seronegative at baseline, both infants and children who received the 640 U adjuvant vaccine had the highest GMTs on day 56 (522&#xb7;8 [403&#xb7;9&#x2013;676&#xb7;6] in infants and 708&#xb7;4 [524&#xb7;1&#x2013;957&#xb7;6] in children), followed by those who received the 320 U adjuvant vaccine (358&#xb7;2 [280&#xb7;5&#x2013;457&#xb7;5] in infants and 498&#xb7;0 [383&#xb7;4&#x2013;646&#xb7;9] in children). 549 (45&#xb7;8%) of 1200 participants (95 CI 42&#xb7;9&#x2013;48&#xb7;6%) reported at least one injection-site or systemic adverse reaction, but the incidence of adverse reactions did not differ significantly between groups (p=0&#xb7;36). The 640 U alum-adjuvant vaccine group had a significantly higher incidence of induration than did the 640 U adjuvant-free group (p=0&#xb7;001).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Taking immunogenicity, safety, and production capacity into account, the 320 U alum-adjuvant formulation of the EV71 vaccine is probably the best possible formulation for phase 3 trials.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">The National Science and Technology Major Project (2011ZX10004-902) of the Chinese Ministry of Science and Technology, China's 12&#x2013;5 National Major Infectious Disease Program (2012ZX10002-001), and Beijing Vigoo Biological.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Feng-Cai</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zheng-Lun</ForeName><Initials>ZL</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiu-Ling</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Heng-Ming</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fan-Yue</ForeName><Initials>FY</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qun-Ying</ForeName><Initials>QY</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Tao</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yue-Mei</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhen-Yu</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing-Xin</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qing-Hua</ForeName><Initials>QH</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qi-Yan</ForeName><Initials>QY</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hui-Jie</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Qin</ForeName><Initials>XQ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yu-Ying</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Feng-Xiang</ForeName><Initials>FX</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Xin-Liang</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun-Zhi</ForeName><Initials>JZ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01399853</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2013 Mar 23;381(9871):976-7. doi: 10.1016/S0140-6736(13)60286-X</RefSource><PMID Version="1">23668563</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23352749</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pii">S0140-6736(12)61764-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>